These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 3515681

  • 1. Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months.
    Feduska NJ, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Salvatierra O.
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):136-40. PubMed ID: 3515681
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The use of low doses of cyclosporine, azathioprine, and prednisone in renal transplantation.
    First MR, Alexander JW, Wadhwa N, Penn I, Munda R, Fidler JP, Weiskittel P.
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):132-5. PubMed ID: 3515680
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequential conventional immunotherapy with maintenance cyclosporine following renal transplantation.
    Sommer BG, Henry ML, Ferguson RM.
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):69-75. PubMed ID: 3515698
    [No Abstract] [Full Text] [Related]

  • 8. A single center experience with "low-dose" cyclosporine in cadaveric renal transplantation.
    Fries D, Hiesse C, Charpentier B, Lantz O, Bensadoun H, Benoit G.
    Clin Transpl; 1988 Apr; ():115-29. PubMed ID: 3154465
    [No Abstract] [Full Text] [Related]

  • 9. Quadruple drug therapy prevents graft loss from acute rejection without increasing mortality.
    Light JA, Aquino A, Ali A, Rodriguez R, Ali S.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1927-30. PubMed ID: 3547897
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dallas experience with cyclosporine A (CsA) one to six months posttransplant.
    Hull AR, Atkins CR, Brinker KR, Dawidson I, Dickerman RM, Emerson W, Helderman JH, Levitz B, Long DL, Nesser D.
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):128-31. PubMed ID: 3515679
    [No Abstract] [Full Text] [Related]

  • 18. Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone-treated recipients.
    Kahan BD, Mickey R, Flechner SM, Lorber MI, Wideman CA, Kerman RH, Terasaki P, Van Buren CT.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1835-8. PubMed ID: 3547890
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.